Can multi-omics signature be used to predict amyloid positivity in asymptomatic Alzheimer’s disease?

Takeaway

  • Multi-omic approaches identifying brain amyloid deposition from peripheral blood, prove successful in identifying asymptomatic individuals at risk for Alzheimer’s disease (AD).

Why this matters

  • Current tests for risk assessment of Alzheimer’s disease can be painful, expensive and have lower predictive power.

  • New multi-omic testing may predict AD pathology in asymptomatic individuals with higher accuracy than previous tests, highlighting the significance of biomarkers in early diagnosis and treatment of AD.